B. Riley initiated coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a report published on Friday, January 5th, Marketbeat reports. The firm issued a neutral rating and a $3.00 target price on the biotechnology company’s stock.
Other research analysts also recently issued research reports about the stock. BidaskClub raised shares of Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, December 27th. Cantor Fitzgerald set a $2.00 target price on shares of Arrowhead Pharmaceuticals and gave the stock a hold rating in a report on Tuesday, December 12th. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. William Blair raised shares of Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. Finally, Piper Jaffray Companies raised shares of Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 target price for the company in a report on Monday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Arrowhead Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $3.13.
Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) traded up $0.68 on Friday, hitting $5.72. 7,343,700 shares of the stock were exchanged, compared to its average volume of 3,400,156. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $6.25. The company has a market cap of $428.02, a P/E ratio of -12.17 and a beta of 1.79. The company has a current ratio of 3.63, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03.
In other Arrowhead Pharmaceuticals news, COO Bruce D. Given sold 20,000 shares of the business’s stock in a transaction dated Monday, January 1st. The shares were sold at an average price of $3.69, for a total value of $73,800.00. Following the completion of the sale, the chief operating officer now owns 948,356 shares of the company’s stock, valued at approximately $3,499,433.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.57% of the company’s stock.
Several large investors have recently modified their holdings of the company. Allianz Asset Management GmbH acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $1,958,000. Dimensional Fund Advisors LP raised its position in shares of Arrowhead Pharmaceuticals by 252.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 31,765 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Arrowhead Pharmaceuticals by 10.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after buying an additional 16,103 shares in the last quarter. ING Groep NV acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $3,500,000. Finally, Virtu KCG Holdings LLC raised its position in shares of Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares in the last quarter. Institutional investors own 20.05% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.